Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 1/20 | 0.42 |
| ▸ | HTR2C | P28335 | 1/20 | 0.38 |
| ▸ | MAOB | P27338 | 2/20 | 0.34 |
| ▸ | PNMT | P11086 | 1/20 | 0.34 |
| ▸ | CD44 | P16070 | 1/20 | 0.34 |
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
| ▸ | DRD2 | P14416 | 1/20 | 0.33 |
| ▸ | DRD1 | P21728 | 1/20 | 0.33 |
| ▸ | DRD4 | P21917 | 1/20 | 0.33 |
| ▸ | DRD5 | P21918 | 1/20 | 0.33 |
| ▸ | DRD3 | P35462 | 1/20 | 0.33 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.32 |
| ▸ | MAOA | P21397 | 1/20 | 0.32 |
| ▸ | KIF11 | P52732 | 1/20 | 0.32 |
| ▸ | PDPK1 | O15530 | 1/20 | 0.31 |
| ▸ | PARP1 | P09874 | 1/20 | 0.31 |
| ▸ | PARP10 | Q53GL7 | 1/20 | 0.31 |
| ▸ | PARP11 | Q9NR21 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10321512 | 0.94 | TSHR (0.46) | TSHRHTR2CMAOBPNMTCD44 | |
| SCHEMBL2998 | 0.87 | HTR2C (0.46) | TSHRHTR2CMAOBPNMTCD44 | |
| SCHEMBL21726 | 0.73 | — | — | |
| SCHEMBL2746647 | 0.73 | — | — | |
| SCHEMBL10321123 | 0.71 | TSHR (0.48) | TSHRHTR2CMAOBPNMTCD44 | |
| SCHEMBL4505345 | 0.67 | HTR2C (0.70) | TSHRHTR2CMAOBPNMTCD44 | |
| SCHEMBL286696 | 0.67 | TSHR (0.48) | TSHRHTR2CMAOBMAPTCYP2A6 | |
| SCHEMBL3884 | 0.67 | TSHR (0.48) | TSHRHTR2CMAOBMAPTCYP2A6 | |
| SCHEMBL25404307 | 0.66 | TSHR (0.93) | TSHRHTR2CMAOBPNMTCD44 | |
| SCHEMBL62945 | 0.65 | TSHR (0.52) | TSHRHTR2CMAOBMAPTCYP2A6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 35 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130303567-A1 | SMALL MOLECULE INHIBITORS OF PARP ACTIVITY | ANGION BIOMEDICA CORP | 2013-11-14 | — | — | US | claimed |
| US-8513433-B2 | Small molecule inhibitors of PARP activity | ANGION BIOMEDICA CORP. (US) | 2013-08-20 | — | — | US | claimed |
| US-20120184533-A1 | SMALL MOLECULE INHIBITORS OF PARP ACTIVITY | ANGION BIOMEDICA CORP. (US) | 2012-07-19 | — | — | US | claimed |
| US-11731954-B2 | Histone demethylase inhibitors | CELGENE QUANTICEL RES INC (US) | 2023-08-22 | — | — | US | disclosed |
| US-20210238161-A1 | HISTONE DEMETHYLASE INHIBITORS | CELGENE QUANTICEL RESEARCH, INC. (US) | 2021-08-05 | — | — | US | disclosed |
| US-11001568-B2 | Histone demethylase inhibitors | CELGENE QUANTICEL RESEARCH, INC. (US) | 2021-05-11 | — | — | US | disclosed |
| US-20200157077-A1 | HISTONE DEMETHYLASE INHIBITORS | CELGENE QUANTICEL RESEARCH, INC. (US) | 2020-05-21 | — | — | US | disclosed |
| US-8957069-B2 | Benzofuran derivatives | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2015-02-17 | — | — | US | disclosed |
| US-8901309-B2 | Fused triazoles for the treatment or prophylaxis of mild cognitive impairment | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2014-12-02 | — | — | US | disclosed |
| US-20140350260-A1 | HETEROCYCLIC COMPOUND AND USE THEREOF | TAKEDA PHARMACEUTICAL (JP) | 2014-11-27 | — | — | US | disclosed |
| EP-2781513-A1 | Benzofuran derivatives | Takeda Pharmaceutical Company Limited (JP) | 2014-09-24 | — | — | EP | disclosed |
| US-20120184533-A1 | SMALL MOLECULE INHIBITORS OF PARP ACTIVITY | ANGION BIOMEDICA CORP. (US) | 2012-07-19 | — | — | US | disclosed |
| EP-2450352-A1 | PROPHYLACTIC OR THERAPEUTIC AGENT FOR CANCER | Takeda Pharmaceutical Company Limited (JP) | 2012-05-09 | — | — | EP | disclosed |
| US-20120088748-A1 | HETEROCYCLIC COMPOUNDS | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2012-04-12 | — | — | US | disclosed |
| US-20120059030-A1 | HETEROCYCLIC COMPOUND AND USE THEREOF | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2012-03-08 | — | — | US | disclosed |
| US-20120046277-A1 | BENZOFURAN DERIVATIVES | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2012-02-23 | — | — | US | disclosed |
| US-20100234357-A1 | Benzofuran derivatives | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2010-09-16 | — | — | US | disclosed |
| US-20100029619-A1 | FUSED HETEROCYCLIC COMPOUND | TAKEDA PHARMACEUTICAL COMPANY LIMTED (JP) | 2010-02-04 | — | — | US | disclosed |
| US-20090270361-A1 | Substituted pyrazole derivatives and use thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2009-10-29 | — | — | US | disclosed |
| EP-2058309-A1 | FUSED HETEROCYCLIC COMPOUND | Takeda Pharmaceutical Company Limited (JP) | 2009-05-13 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (13 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090270361-A1 | Substituted pyrazole derivatives and use thereof | CBR3, CBR1, NOX5 | TSHR 874/4885HTR2C 514/4885MAOB 288/4885 |
| US-20120059030-A1 | HETEROCYCLIC COMPOUND AND USE THEREOF | BACE1, BACE2, APP | TSHR 4610/4885HTR2C 2223/4885MAOB 824/4885 |
| US-11001568-B2 | Histone demethylase inhibitors | KDM1B, KDM1A, BMI1 | TSHR 2436/4885HTR2C 3952/4885MAOB 834/4885 |
| US-20100029619-A1 | FUSED HETEROCYCLIC COMPOUND | IRAK1, IL1R1, IRAK2 | TSHR 1751/4885HTR2C 1561/4885MAOB 2966/4885 |
| US-20100234357-A1 | Benzofuran derivatives | AHR, BRPF3, CBR3 | TSHR 2302/4885HTR2C 10/4885MAOB 585/4885 |
| US-11731954-B2 | Histone demethylase inhibitors | KDM1B, KDM1A, BMI1 | TSHR 2436/4885HTR2C 3952/4885MAOB 834/4885 |
| US-20130303567-A1 | SMALL MOLECULE INHIBITORS OF PARP ACTIVITY | PARP1, PARP11, PARP15 | TSHR 4709/4885HTR2C 4262/4885MAOB 643/4885 |
| US-20120184533-A1 | SMALL MOLECULE INHIBITORS OF PARP ACTIVITY | PARP1, PARP11, PARP15 | TSHR 4709/4885HTR2C 4262/4885MAOB 643/4885 |
| US-20140350260-A1 | HETEROCYCLIC COMPOUND AND USE THEREOF | BACE1, BACE2, APP | TSHR 4610/4885HTR2C 2223/4885MAOB 824/4885 |
| US-20120088748-A1 | HETEROCYCLIC COMPOUNDS | SLC6A2, MAOB, MAOA | TSHR 757/4885HTR2C 12/4885MAOB 2/4885 |
| US-20200157077-A1 | HISTONE DEMETHYLASE INHIBITORS | KDM1B, KDM1A, BMI1 | TSHR 2436/4885HTR2C 3952/4885MAOB 834/4885 |
| US-20120046277-A1 | BENZOFURAN DERIVATIVES | BRPF3, BRD1, CBR3 | TSHR 2018/4885HTR2C 318/4885MAOB 983/4885 |
| US-20210238161-A1 | HISTONE DEMETHYLASE INHIBITORS | KDM1B, KDM1A, BMI1 | TSHR 2436/4885HTR2C 3952/4885MAOB 834/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.